Estimating costs of adverse events (AEs) and healthcare resource use (HRU) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) receiving tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel): A summary of real-world evidence.

被引：0
|
作者：
Yang, Hongbo
Qi, Cynthia Zhengyun
Dalal, Anand
Bollu, Vamsi
Zhang, Jie
Zhang, Su
Lim, Stephen
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e19551
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19551
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.
    Jaeger, Ulrich
    Worel, Nina
    McGuirk, Joseph
    Riedell, Peter A.
    Fleury, Isabelle
    Borchmann, Peter
    Du, Yan
    Abdelhady, Ahmed M.
    Han, Xia
    Martinez-Prieto, Marcela
    Waller, Edmund K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD OF CARE FOR ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN SWEDEN, NORWAY, FINLAND, AND DENMARK
    Karampampa, K.
    Stene, E.
    Axelsen, F.
    Lyngaa, R.
    Vadgama, S.
    Jerkeman, M.
    Wilen-Koort, A.
    Wallace, K.
    VALUE IN HEALTH, 2020, 23 : S687 - S687
  • [33] Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience
    Nastoupil, Loretta J.
    Jain, Michael D.
    Spiegel, Jay Y.
    Ghobadi, Armin
    Lin, Yi
    Dahiya, Saurabh
    Lunning, Matthew A.
    Lekakis, Lazaros J.
    Reagan, Patrick M.
    Oluwole, Olalekan O.
    McGuirk, Joseph P.
    Deol, Abhinav
    Sehgal, Alison R.
    Goy, Andre
    Hill, Brian T.
    Andreadis, Charalambos
    Munoz, Javier
    Westin, Jason R.
    Chavez, Julio C.
    Cashen, Amanda F.
    Bennani, Nora N.
    Rapoport, Aaron P.
    Vose, Julie M.
    Miklos, David B.
    Neelapu, Sattva S.
    Locke, Frederick L.
    BLOOD, 2018, 132
  • [34] Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)
    Bharadwaj, Sushma
    Lau, Eric
    Goyal, Anmol
    Hamilton, Mark P.
    Srinagesh, Hrishikesh
    Jensen, Alexandria
    Syal, Shriya
    Mallampet, Jayasindhu
    Latchford, Theresa
    Sahaf, Bita
    Weng, Wen-Kai
    Smith, Melody
    Maecker, Holden T.
    Frank, Matthew J.
    Miklos, David B.
    Dahiya, Saurabh
    BLOOD, 2023, 142
  • [35] Matching-Adjusted Indirect Comparison (MAIC) of Axicabtagene Ciloleucel (Axi-Cel) and Lisocabtagene Maraleucel (Liso-Cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) After Two or More Prior Lines of Therapy
    Oluwole, Olalekan O.
    Chen, Jenny M. H.
    Chan, Keith
    Patel, Anik R.
    Jansen, Jeroen P.
    Keeping, Sam
    Bashir, Zahid
    Zheng, Yan
    Snider, Julia
    Locke, Frederick L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S388 - S388
  • [36] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
    Oluwole, Olalekan O.
    Forcade, Edouard
    Munoz, Javier
    de Guibert, Sophie
    Vose, Julie M.
    Bartlett, Nancy L.
    Lin, Yi
    Deol, Abhinav
    McSweeney, Peter A.
    Goy, Andre H.
    Kersten, Marie Jose
    Jacobson, Caron A.
    Farooq, Umar
    Minnema, Monique C.
    Thieblemont, Catherine
    Timmerman, John
    Stiff, Patrick
    Avivi, Irit
    Tzachanis, Dimitrios
    Zheng, Yan
    Vardhanabhuti, Saran
    Nater, Jenny
    Shen, Rhine R.
    Miao, Harry
    Kim, Jenny
    van Meerten, Tom
    BLOOD, 2022, 140 : 10399 - 10401
  • [37] Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World
    Peters, Anthea
    Nowakowski, Grzegorz S.
    Dabas, Rosy
    Amoloja, Theresa
    Xue, Zhenyi
    Koch, Caroline
    Waltl, Eva E.
    Fleury, Isabelle
    BLOOD, 2022, 140 : 3811 - 3813
  • [38] Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)
    Bharadwaj, Sushma
    Lau, Eric
    Hashmi, Ayesha
    Hamilton, Mark P.
    Jensen, Alexandria
    Goyal, Anmol
    Marar, Mallika
    Lee, Caroline
    Ananth, Snegha
    Sahaf, Bita
    Mallampet, Jayasindhu
    Ehlinger, Zachary
    Syal, Shriya
    Patil, Sunita
    Guo, Henry
    Smith, Melody
    Weng, Wen-Kai
    Frank, Matthew J.
    Binkley, Michael S.
    Miklos, David B.
    Dahiya, Saurabh
    BLOOD, 2023, 142
  • [39] Primary Analysis of ZUMA7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) versus StandardofCare (SOC) Therapy in Patients (Pts) with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Ghobadi, Armin
    Locke, Frederick L.
    Miklos, David B.
    Jacobson, Caron A.
    Perales, Miguel-Angel
    Kersten, Marie Jose
    Oluwole, Olalekan O.
    Rapoport, Aaron P.
    McGuirk, Joseph P.
    Pagel, John M.
    Munoz, Javier
    Farooq, Umar
    van Meerten, Tom
    Reagan, Patrick M.
    Sureda, Anna
    Flinn, Ian W.
    Vandenberghe, Peter
    Song, Kevin W.
    Dickinson, Michael
    Minnema, Monique C.
    Riedell, Peter A.
    Leslie, Lori A.
    Chaganti, Sridhar
    Yang, Yin
    Filosto, Simone
    Schupp, Marco
    To, Christina
    Cheng, Paul
    Gordon, Leo I.
    Westin, Jason R.
    MOLECULAR THERAPY, 2022, 30 (04) : 519 - 519
  • [40] Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States
    Maziarz, Richard T.
    Yang, Hongbo
    Liu, Qing
    Wang, Travis
    Zhao, Jing
    Lim, Stephen
    Lee, Soyon
    Dalal, Anand
    Bollu, Vamsi
    LEUKEMIA & LYMPHOMA, 2022, 63 (09) : 2052 - 2062
12345